INTUITIVE SURGICAL INC (IUI1.DE) Stock Fundamental Analysis
Europe - FRA:IUI1 - US46120E6023 - Common Stock
470.65 EUR
+3 (+0.64%)
Overall IUI1 gets a fundamental rating of 6 out of 10. We evaluated IUI1 against 60 industry peers in the Health Care Equipment & Supplies industry. IUI1 has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. IUI1 is valued quite expensive, but it does show an excellent growth. These ratings would make IUI1 suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
IUI1 had positive earnings in the past year.
IUI1 had a positive operating cash flow in the past year.
In the past 5 years IUI1 has always been profitable.
IUI1 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
IUI1's Return On Assets of 12.93% is amongst the best of the industry. IUI1 outperforms 90.00% of its industry peers.
IUI1 has a better Return On Equity (14.61%) than 80.00% of its industry peers.
The Return On Invested Capital of IUI1 (10.09%) is better than 83.33% of its industry peers.
IUI1 had an Average Return On Invested Capital over the past 3 years of 9.53%. This is in line with the industry average of 9.00%.
The 3 year average ROIC (9.53%) for IUI1 is below the current ROIC(10.09%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.93% | ||
| ROE | 14.61% | ||
| ROIC | 10.09% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
1.3 Margins
IUI1's Profit Margin of 28.51% is amongst the best of the industry. IUI1 outperforms 95.00% of its industry peers.
In the last couple of years the Profit Margin of IUI1 has declined.
IUI1 has a Operating Margin of 28.96%. This is amongst the best in the industry. IUI1 outperforms 98.33% of its industry peers.
In the last couple of years the Operating Margin of IUI1 has declined.
Looking at the Gross Margin, with a value of 66.61%, IUI1 is in the better half of the industry, outperforming 73.33% of the companies in the same industry.
IUI1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.96% | ||
| PM (TTM) | 28.51% | ||
| GM | 66.61% |
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IUI1 is creating some value.
The number of shares outstanding for IUI1 has been increased compared to 1 year ago.
IUI1 has more shares outstanding than it did 5 years ago.
IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
IUI1 has an Altman-Z score of 51.71. This indicates that IUI1 is financially healthy and has little risk of bankruptcy at the moment.
IUI1 has a Altman-Z score of 51.71. This is amongst the best in the industry. IUI1 outperforms 100.00% of its industry peers.
IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 51.71 |
ROIC/WACC1.15
WACC8.74%
2.3 Liquidity
A Current Ratio of 5.17 indicates that IUI1 has no problem at all paying its short term obligations.
With an excellent Current ratio value of 5.17, IUI1 belongs to the best of the industry, outperforming 95.00% of the companies in the same industry.
A Quick Ratio of 4.18 indicates that IUI1 has no problem at all paying its short term obligations.
The Quick ratio of IUI1 (4.18) is better than 95.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.17 | ||
| Quick Ratio | 4.18 |
3. Growth
3.1 Past
IUI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.12%, which is quite impressive.
IUI1 shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 11.48% yearly.
Looking at the last year, IUI1 shows a very strong growth in Revenue. The Revenue has grown by 22.18%.
The Revenue has been growing by 13.27% on average over the past years. This is quite good.
EPS 1Y (TTM)28.12%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%30.43%
Revenue 1Y (TTM)22.18%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%22.91%
3.2 Future
Based on estimates for the next years, IUI1 will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.53% on average per year.
IUI1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.89% yearly.
EPS Next Y13.5%
EPS Next 2Y13.63%
EPS Next 3Y14.59%
EPS Next 5Y14.53%
Revenue Next Year19.68%
Revenue Next 2Y17.01%
Revenue Next 3Y16.2%
Revenue Next 5Y14.89%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 62.84 indicates a quite expensive valuation of IUI1.
60.00% of the companies in the same industry are cheaper than IUI1, based on the Price/Earnings ratio.
IUI1 is valuated expensively when we compare the Price/Earnings ratio to 26.13, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 57.15, IUI1 can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, IUI1 is valued a bit more expensive than 65.00% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of IUI1 to the average of the S&P500 Index (22.35), we can say IUI1 is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 62.84 | ||
| Fwd PE | 57.15 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IUI1 is valued a bit more expensive than 65.00% of the companies in the same industry.
IUI1's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 97.21 | ||
| EV/EBITDA | 57.44 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IUI1 does not grow enough to justify the current Price/Earnings ratio.
IUI1 has a very decent profitability rating, which may justify a higher PE ratio.
IUI1's earnings are expected to grow with 14.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.65
PEG (5Y)5.47
EPS Next 2Y13.63%
EPS Next 3Y14.59%
5. Dividend
5.1 Amount
No dividends for IUI1!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:IUI1 (11/5/2025, 7:00:00 PM)
470.65
+3 (+0.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners88.66%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap168.72B
Revenue(TTM)9.61B
Net Income(TTM)2.61B
Analysts79
Price Target522 (10.91%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.33%
Min EPS beat(2)3.05%
Max EPS beat(2)11.61%
EPS beat(4)4
Avg EPS beat(4)11.45%
Min EPS beat(4)3.05%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)8.83%
EPS beat(12)11
Avg EPS beat(12)6.4%
EPS beat(16)13
Avg EPS beat(16)4.58%
Revenue beat(2)2
Avg Revenue beat(2)1.47%
Min Revenue beat(2)1.09%
Max Revenue beat(2)1.84%
Revenue beat(4)3
Avg Revenue beat(4)1.98%
Min Revenue beat(4)-0.14%
Max Revenue beat(4)5.12%
Revenue beat(8)4
Avg Revenue beat(8)0.5%
Revenue beat(12)6
Avg Revenue beat(12)0.42%
Revenue beat(16)7
Avg Revenue beat(16)0.13%
PT rev (1m)3.71%
PT rev (3m)0.85%
EPS NQ rev (1m)-0.43%
EPS NQ rev (3m)-0.24%
EPS NY rev (1m)-0.04%
EPS NY rev (3m)4.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.16%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)0.1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 62.84 | ||
| Fwd PE | 57.15 | ||
| P/S | 21.2 | ||
| P/FCF | 97.21 | ||
| P/OCF | 68.6 | ||
| P/B | 10.86 | ||
| P/tB | 11.09 | ||
| EV/EBITDA | 57.44 |
EPS(TTM)7.49
EY1.59%
EPS(NY)8.24
Fwd EY1.75%
FCF(TTM)4.84
FCFY1.03%
OCF(TTM)6.86
OCFY1.46%
SpS22.2
BVpS43.32
TBVpS42.43
PEG (NY)4.65
PEG (5Y)5.47
Graham Number85.45
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.93% | ||
| ROE | 14.61% | ||
| ROCE | 14.34% | ||
| ROIC | 10.09% | ||
| ROICexc | 14.32% | ||
| ROICexgc | 14.73% | ||
| OM | 28.96% | ||
| PM (TTM) | 28.51% | ||
| GM | 66.61% | ||
| FCFM | 21.81% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
ROICexc(3y)14.41%
ROICexc(5y)14.87%
ROICexgc(3y)15.07%
ROICexgc(5y)15.72%
ROCE(3y)13.54%
ROCE(5y)13.16%
ROICexgc growth 3Y-7.59%
ROICexgc growth 5Y-7%
ROICexc growth 3Y-6.87%
ROICexc growth 5Y-6.06%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
F-Score6
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 144.66% | ||
| Cap/Sales | 9.1% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 87.68% | ||
| Profit Quality | 76.48% | ||
| Current Ratio | 5.17 | ||
| Quick Ratio | 4.18 | ||
| Altman-Z | 51.71 |
F-Score6
WACC8.74%
ROIC/WACC1.15
Cap/Depr(3y)197.35%
Cap/Depr(5y)162.98%
Cap/Sales(3y)12.27%
Cap/Sales(5y)10.16%
Profit Quality(3y)56.77%
Profit Quality(5y)75.99%
High Growth Momentum
Growth
EPS 1Y (TTM)28.12%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%30.43%
EPS Next Y13.5%
EPS Next 2Y13.63%
EPS Next 3Y14.59%
EPS Next 5Y14.53%
Revenue 1Y (TTM)22.18%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%22.91%
Revenue Next Year19.68%
Revenue Next 2Y17.01%
Revenue Next 3Y16.2%
Revenue Next 5Y14.89%
EBIT growth 1Y34.8%
EBIT growth 3Y8.76%
EBIT growth 5Y11.37%
EBIT Next Year40.01%
EBIT Next 3Y23.66%
EBIT Next 5Y20.2%
FCF growth 1Y69.15%
FCF growth 3Y-9.1%
FCF growth 5Y2.14%
OCF growth 1Y52.09%
OCF growth 3Y4.95%
OCF growth 5Y8.61%
INTUITIVE SURGICAL INC / IUI1.DE FAQ
Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to IUI1.DE.
What is the valuation status of INTUITIVE SURGICAL INC (IUI1.DE) stock?
ChartMill assigns a valuation rating of 1 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.
Can you provide the profitability details for INTUITIVE SURGICAL INC?
INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 7 / 10.
What are the PE and PB ratios of INTUITIVE SURGICAL INC (IUI1.DE) stock?
The Price/Earnings (PE) ratio for INTUITIVE SURGICAL INC (IUI1.DE) is 62.84 and the Price/Book (PB) ratio is 10.86.
What is the earnings growth outlook for INTUITIVE SURGICAL INC?
The Earnings per Share (EPS) of INTUITIVE SURGICAL INC (IUI1.DE) is expected to grow by 13.5% in the next year.